167 related articles for article (PubMed ID: 21059700)
1. An update on the use of indacaterol in patients with COPD.
Brienza NS; Amor-Carro O; Ramos-Barbón D
Ther Adv Respir Dis; 2011 Feb; 5(1):29-40. PubMed ID: 21059700
[TBL] [Abstract][Full Text] [Related]
2. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
3. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
Beeh KM; Beier J
Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
[TBL] [Abstract][Full Text] [Related]
4. Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.
Steiropoulos P; Papanas N; Nena E; Bouros D
Expert Opin Pharmacother; 2012 May; 13(7):1015-29. PubMed ID: 22471750
[TBL] [Abstract][Full Text] [Related]
5. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Beeh KM; Beier J
Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
Ribeiro M; Chapman KR
Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
[TBL] [Abstract][Full Text] [Related]
7. Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
Prescrire Int; 2011 Sep; 20(119):201-5. PubMed ID: 21954512
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
9. Indacaterol: a novel long-acting β(2) -agonist.
Ray SM; McMillen JC; Treadway SA; Helmer RS; Franks AS
Pharmacotherapy; 2012 May; 32(5):456-74. PubMed ID: 22499359
[TBL] [Abstract][Full Text] [Related]
10. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Kerwin EM; Williams J
Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
[TBL] [Abstract][Full Text] [Related]
11. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
Tashkin DP
Expert Opin Pharmacother; 2010 Aug; 11(12):2077-85. PubMed ID: 20642373
[TBL] [Abstract][Full Text] [Related]
12. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
Pearlman DS; Greos L; LaForce C; Orevillo CJ; Owen R; Higgins M
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
[TBL] [Abstract][Full Text] [Related]
13. Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.
Beier J; Beeh KM
Int J Chron Obstruct Pulmon Dis; 2011; 6():237-43. PubMed ID: 21814459
[TBL] [Abstract][Full Text] [Related]
14. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Beeh KM; Wagner F; Khindri S; Drollmann AF
COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
16. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
17. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
Chen AM; Bollmeier SG; Finnegan PM
Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
[TBL] [Abstract][Full Text] [Related]
18. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
van Noord JA; Buhl R; Laforce C; Martin C; Jones F; Dolker M; Overend T
Thorax; 2010 Dec; 65(12):1086-91. PubMed ID: 20978028
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
[TBL] [Abstract][Full Text] [Related]
20. The effect of indacaterol during an acute exacerbation of COPD.
Segreti A; Fiori E; Calzetta L; Sabatini M; Segreti V; Rogliani P; Cazzola M
Pulm Pharmacol Ther; 2013 Dec; 26(6):630-4. PubMed ID: 23578980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
